⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL98083 | 0.87 | — | — | |
| SCHEMBL3020365 | 0.77 | — | — | |
| SCHEMBL96803 | 0.77 | — | — | |
| SCHEMBL1897478 | 0.76 | ALDH1A1 (0.32) | — | |
| SCHEMBL1895073 | 0.76 | ALDH1A1 (0.38) | — | |
| SCHEMBL2913315 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL1894593 | 0.76 | ALDH1A1 (0.43) | — | |
| SCHEMBL887220 | 0.76 | — | — | |
| SCHEMBL911290 | 0.76 | EPHX2 (0.30) | — | |
| SCHEMBL18454688 | 0.76 | DRD2 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| US-20090035851-A1 | Modulators Of NOD1 Signaling | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1948211-A2 | MODULATORS OF NOD1 SIGNALING | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007044989-A2 | MODULATORS OF NOD1 SIGNALING | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060258580-A1 | Such as N-acyl/myristoyl-gamma-glucose-diaminopimelic acid dipeptides; for activation of nuclear factor kappa beta; for treatment of inflammatory diseases such as Crohn's disease and asthma; drug screening | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-16 | — | — | US | disclosed |